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ABSTRACT 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not 
Methotrexate (MTX) is an effective treatment in partially or totally reducing the symptoms of 
Myasthenia Gravis (MG) patients. 
STUDY DESIGN:  Review of three English language studies; one Case Series Study following 
3 patients with concomitant MG and Rheumatoid Arthritis treated with MTX published in 2014, 
one Single-Blind Randomized Control Trial (RCT) comparing MTX and AZA (Azathioprine) 
published in 2011, and one Double-blind, placebo-controlled Randomized Control Trial 
published in 2016. 
DATA SOURCES:  Three primary research studies published in peer reviewed journals; found 
on the PubMed database.  Each study’s results included patient oriented outcomes that were 
relevant to this selective EBM review. 
OUTCOMES MEASURED:  Each study assessed the MG outcomes and quality of life 
measures after treatment with Methotrexate.  The two RCTs used the following assessment tools 
to quantify their outcomes:  Quantitative MG (QMG) Score, Manual Muscle Testing (MMT), 
MG Quality of Life (MGQOL), MG-Activities of Daily Living (MG-ADL), Minimum 
Manifestations Status (MMS), and MG Composite Change. 
RESULTS: The Case Series Study showed an association between MTX and improved MG 
symptoms; however it did not show cause and effect.  The Single-Blind RCT compared MTX 
and AZA (enrollment: AZA n = 15; MTX n = 16).  Similarities between both groups were found 
in regards to MMS after 24 months (AZA n = 7; MTX n = 9; p = 0.83; ABI = .03; NNT = 34), 
and safety; giving promise to MTX’s efficacy. The Double-blind, placebo-controlled RCT 
(enrollment: MTX n = 25; Placebo n = 25) found MTX did not improve QMG, MMT, MGQOL, 
MG-ADL, or MG Composite Change over 12 months.  Withdrawals: Placebo n = 7; MTX n = 1; 
no serious MTX-related adverse events were encountered.  Both RCT’s data was determined to 
be not statistically significant due to small enrollment size. P-values were >0.05 and 95% CI 
were too wide to be precise. 
CONCLUSION:  Based on the Case Series Study and two RCTs, MTX is not an effective 
treatment in partially or totally reducing the symptoms of MG patients. 
KEY WORDS:  Myasthenia Gravis, Methotrexate 
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INTRODUCTION 
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular condition associated 
with weakness and fatigability of voluntary skeletal muscles of the body3.  Muscles most 
commonly affected control eye movement, the eye lids, chewing, swallowing, coughing and 
facial expressions; less commonly affected are the muscles used to control breathing and the 
movement of extremities6.  This review evaluates one Case Series Study and two Randomized 
Control Trials (RCTs) which study Methotrexate (MTX) to determine if it can reduce or 
eliminate the symptoms of MG patients. 
It is estimated that 20 out of every 100,000 individuals in the United States have been 
diagnosed with MG; this equates to approximately 60,000 people.  MG is believed, however, to 
be a significantly underdiagnosed disease and the prevalence is probably much higher.6 
In a 2009 study, costs related to the treatment of MG were higher than those of other 
chronic neurological diseases.  The average total annual health plan cost for MG patients was 
$20,190. $15,675 of which was attributed to the treatment of MG.  Match-paired controls had an 
average total annual health plan cost of only $4,515.  The MG annual costs were broken down as 
follows: 23% in Home Health (includes IVIg costs), 17% in MD office visits, 8% in Pharmacy 
costs (does not include IVIg costs), 27% in Inpatient services, and 23% in Outpatient services.  
Total annual MG-related pharmacological costs were $9.4 million.  Pharmacological costs were 
as follows: 85% IVIg, 9.3% non-steroidal immunosuppressants, 5.7% cholinesterase inhibitors, 
and 0.2% corticosteroids.7 
MG’s muscle weakness is due to circulating antibodies which are produced by plasma 
cells, part of the body’s own immune system, which block or destroy as much as 80% of 
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acetylcholine receptors at the postsynaptic junctions.  This leads to the inhibition of skeletal 
muscle contractions.3,6 Common symptoms include ptosis, blurred vision, diplopia, dysphonia, 
difficulty chewing, dysphagia, extremity weakness, muscle fatigue and dyspnea.  Muscle 
weakness tends to increase with continued use and improves with periods of rest.  Symptoms 
vary for each patient and can fluctuate throughout a patient’s life.  MG occurs in all races, both 
genders and at any age.   No strong genetic components have not been found, however it does 
occasionally occur in more than one member of a family.  MG is not an infectious disease, 
therefore it is not contagious.  Currently the cause of MG is unknown, and there is no cure for 
this disease.6 
There are various methods to treat MG; treatments are individualized to each patient 
based on the severity of their symptoms, their sex, age, and degree of impairment.  First-line 
therapy for symptomatic treatment is an anti-acetylcholinesterase agent, which allows the 
neurotransmitter Acetylcholine to remain at the neuromuscular junction longer so that more 
receptors can be activated.6,11   
Other first-line MG treatments are aimed at suppressing the immune system and the 
associated antibody response to induce remission, prevent disease progression and restore 
function at the neuromuscular junction11. Corticosteriods alone or in combination with other 
immunosuppressant drugs are disease modifying agents for MG.  Corticosteriods, such as 
Prednisone, can be quite effective in reducing MG symptoms. However, they have serious dose-
limiting side effects including generalized immunosuppression, hyperglycemia, hypertension, 
myopathy, weight gain, cataracts, and osteoporosis.  Azathioprine (AZA) and Cyclosporine are 
the only immunosuppressants proven to be effective for treating MG in RCTs when compared to 
placebos.9 They are often used as steroid-sparing therapies, either reducing the need for or lower 
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the corticosteroid doses, sparing the patient the steroid’s adverse side effects.  These 
immunosuppressants however, come with their own sets of side effects.  Cyclosporine is 
associated with hypertension, renal insufficiency, and hirsutism.  AZA is associated with 
systemic hypersensitivity, hepatotoxicity, and myelosuppression.5 
Methotrexate has been used and proven to be effective in the treatment of other 
autoimmune disorders, such as Rheumatoid Arthritis (RA), Crohn’s disease, and Multiple 
Sclerosis.  It has many advantages include PO dosing once a week, a generic formulation, a 
moderate side effect profile, inexpensive cost compared to other immunosuppressants like AZA, 
easy accessibility, and the potential to be used for longer periods of time compared to 
corticosteroids.2,5,11    
OBJECTIVE 
The objective of this selective Evidence Based Medicine (EBM) review is to determine 
whether or not Methotrexate (MTX) is an effective treatment in partially or totally reducing the 
symptoms of Myasthenia Gravis (MG) patients. 
METHODS 
 The criteria used to select the studies for this EBM review include: the population studied 
was over the age of 18 years old, who were diagnosed with Myasthenia Gravis class II, III, or IV, 
who were stable on prednisone, but were not on any steroid-sparing immunosuppressants.  Table 
1 provides additional demographics and characteristics for the three studies included in this 
review which include one Case Series Study and two Randomized Control Trials.  The common 
intervention among the studies was MTX.  Comparison groups in the two RCTs included 
experimental groups that received AZA in one study or a placebo in the second study.  Outcomes 
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measured included MG outcomes and quality of life measures, all of which assess MG symptom 
improvement.   
The studies were found by the author using key words “Myasthenia Gravis” and 
“Methotrexate” in the PubMed database.  All three studies were published in English in peer 
reviewed journals.  The sources were selected based on relevance to the clinical question and 
inclusion of patient oriented outcomes (POEMs).  Inclusion criteria for the sources included that 
the studies must be a type of primary research study published within the last 15 years.  
Exclusion criteria for the sources included patients under the age of 18, patients who had recent 
thymectomies, or patients who were treated with an immunosuppressive therapy within the last 
60 days with exception of Prednisone.  A summary of the statistics reported or used in regard to 
the two RCTs include: p-values and 95% CI (Confidence Interval) which were provided in the 
studies, as well as CER (Control Event Rate), EER (Experimental Event Rate), ABI (Absolute 
Benefit Increase), RBI (Relative Benefit Increase) and NNT (Number Needed to Treat) which 
were calculated. 
Table 1 – Demographics & Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W
/D 
Interventions 
Karahmet3 
(2014) 
Case  
Series 
Study 
3 31,36,
& 60 
Patients with 
concomitant MG & 
RA 
N/A 0 MTX 15 mg 
weekly 
Heckman2 
(2011) 
Single 
Blind 
RCT 
31 AZA: 
42.7 
+/-16.8 
 
MTX:  
47.9 
+/- 
14.8 
Diagnosed within 
previous 6 months 
with MGFA class II, 
III, or IV.  Severity of 
functional disability 
of ADLs where 
immunosuppressive 
therapy is indicated 
due to Pyridostigmine 
failure as a 
monotherapy. 
 
Those with MG 
confined to the 
EOM or 
concomitant illness 
such as uncontrolled 
thyroid disease or 
additional 
polymyositis, or 
subjects with HBV 
or HIV infections.   
6 MTX (17.5 mg 
weekly + Folate 
25 mg weekly) 
 
or 
 
AZA (2.5 mg/kg 
daily) 
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Barohn1 
(2015) 
Pasnoor4 
(2014) 
Pasnoor5 
(2012) 
Pasnoor9 
(2016) 
Double 
Blind  
RCT 
50 18+ 
years 
old; 
26.6 to 
87.2 
(full 
range) 
MGFA grade 2, 3, or 
4; stable on 10 
mg/day of Prednisone 
or equivalent with 
alternate day dosing x 
30 days.  
Thymoma, 
thymectomy (within 
last 3 months), 
tumor, infection, 
hepatic / renal 
insufficiency, or 
ILD. On 
immunosuppressive 
therapy w/in last 60 
days.  Prior use of 
MTX within prior 2 
years. Daily NSAID 
use. 
8 MTX  
or  
Placebo 
 
Dosing: 10 mg 
weekly x 2 
weeks, then 15 
mg x 2 weeks, 
then 20 mg 
weekly until the 
end of the study 
(+ Folic acid 
daily). 
 
OUTCOMES MEASURED 
For the Case Series Study, outcomes addressed were improvement in muscle weakness 
and fatigue, however no specifics were provided in how the outcomes were measured over the 
one year period of follow-up.3 
For the Single-blind, MTX vs. AXA RCT, the Quantitative MG (QMG) score and the 
MG Activities of Daily Living (MG-ADL) score were calculated to determine those with 
Minimum Manifestations Status (MMS) of MG.  Visits were scheduled at baseline, 1, 2, 4, and 6 
months after study entry, followed by visits every 3 months for 2 years.  At each visit the 
patient’s progress was assessed by blind assessors.  Outcomes were analyzed in as per-protocol 
analysis in which data measurements of those who withdrew were censored after the date on 
which they were no longer on the study medication.  Data of all subjects were included in the 
denominator for proportionate outcomes such as MMS, number of failures and “responders”.  
Only those who reached sustained MMS up until the end of the 24-month study were considered 
relevant.  Patients were questioned at each visit in regards to compliance; with non-compliance, 
the recorded dose reflected the dose that was taken.2 
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For the Double-blind, placebo-controlled RCT, MG outcomes and quality of life 
measures were analyzed using the QMG, MG-ADL, Manual Muscle Testing (MMT), MG 
Quality of Life (MGGOL), and MG Composite (MGC) change over 12 months; each were 
evaluated every four weeks for 12 months.  Data was analyzed in an intent-to-treat fashion, using 
multiple imputation method for any missing data.1,9 See Table 2 for detailed descriptions of 
outcome measurements. 
Table 2 – Outcome Measurements & Descriptions 
Outcome 
Measurements 
Description of Measurements 
QMG 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, 
along with respiratory function.  Scale of 0-3 for each item, with 0 = normal, 3 = 
severe.  Total score can range from 0-39. Time frame: Change from Baseline to 
completion of study.1 
MG-ADL 8 item scale to assess MG symptoms.  0 = normal to 24 = severe. Time frame: 
Change from Baseline to completion of study.1 
MMT Measures the strength of muscle groups in face, neck, arms, and legs; grading 
amount of weakness.  Normal = 0, mild = 1, moderate = 2, severe = 3, unable to 
perform = 4.  Total score can range from 0-76.  Time frame: Change from Baseline 
to Month 12.1 
MGQOL 15 item patient-reported scale indicating how MG affects QOL per the past 7 days.  
0 = not all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much.  Total score 
can range from 0-76.  Time frame: Change from Baseline to Month 12.1 
MGC change over 
12 months 
Composite of the QMG, MG-ADL, and MMT; each item was weighted and then 
assigned a score.  0 = no effects of MG; 50 = being in the hospital on a ventilator.  
Time frame: Change from Baseline to Month 12.1 
 
RESULTS 
 In the Case Series Study, three patients with concomitant MG and RA were treated with 
15 mg of MTX weekly and were followed for one year.  The MTX treatment was given to treat 
the RA, however all three patients experience beneficial effects in their MG symptoms of muscle 
weakness and fatigue.  The study did not provide continuous or dichotomous data in regards to 
its results, nor was it a controlled trial.  This study shows an association between MTX and 
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improved MG symptoms; however it does not show cause and effect.  When considering the side 
effects of other immunosuppressive therapies, the researchers believed MTX could be an 
effective treatment for MG. They acknowledge that more detailed studies are needed to 
determine the exclusive role of MTX in regard to MG.3   
 Between 2005 and 2010, thirty-one subjects entered the Single-blind, MTX vs. AZA, 
RCT.  Twenty-four subjects were randomized to either MTX (n=11) or AZA (n=13).  The 
remaining seven subjects were not randomized. The majority were due to economic restraints 
which did not allow them the ability to afford the more expensive AZA if randomized to that 
group, therefore they were included in the MTX group (n=5). The two remaining participants 
demanded the Standard of Care treatment of AZA (n=2).  Baseline values between the MTX and 
AZA group, including: duration of MG symptoms, proportion of Prednisone, baseline 
bodyweight, MGFA severity grade, and QMG scores were similar.  Results showed that similar 
proportions of subjects in each group reached sustained MMS by the end of the 24 month trial 
(AZA n = 7; MTX n = 9; p = 0.83).  The MTX-group’s median time to sustained MMS was 10.5 
months, where the AZA-group’s median time to sustained MMS was 12-15 months.  The MMS 
treatment outcomes were used to calculate ABI and NNT for this study; refer to Table 3.   
Table 3 
MMS Treatment Outcomes at 6-monthly intervals2 
 6 months 12 months 18 months 24 months 
AZA, 
n (%) 
2/15 (13%) 4/15 (27%) 5/15 (33%) 7/15 (53%) 
MTX, 
n (%) 
3/16 (19%) 5/16 (31%) 5/16 (31%) 9/16 (56%) 
Treatment Effect of MTX vs. AZA 
CER EER RBI ABI NNT P-Value 
.53 .56 .06 .03 34 0.83 
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According to this study, for every 34 patients treated with MTX, one additional MG 
patient will sustain MMS, compared to patients treated with AZA.  The p-value for the treatment 
effect of MTX vs. AZA is 0.83. Since the p-value is >0.05, this shows that the findings are not 
statistically significant due to the small subject group size of 31 participants.  In regards to the 
safety of the study, intolerable diarrhea (AZA n = 1; MTX n = 1), hearing loss and acne (AZA n 
= 1), and loss of appetite (MTX n = 1) accounted for the study withdrawals, showing that AZA 
and MTX were equally well tolerated.2   
In summary, MTX has an earlier onset of action, similar efficacy and tolerability to AZA, 
demonstrating prolonged remission from MG symptoms; also MTX may be the drug of choice in 
financially constrained patients.2    
Between April 2009 and September 2014, 50 subjects entered a Double-blind, placebo-
controlled RCT (MTX n = 25; Placebo n = 25) at 19 sites across the U.S. and Canada conducted 
by The Methotrexate in MG Investigators of the Muscle Study Group.  Baseline values including 
age, gender, self-reported race/ethnicity, clinical MG parameters and Prednisone dosing were 
similar between both groups. The data included in this trial was continuous. The author reported 
Change in mean from Baseline to Month 12 and t-test values; Table 4 summarizes these values.9 
Table 4 – Treatment Effect of MTX vs. Placebo1,9 
QMG Score (12 month change); method: t-test, 2 sided; groups: All Groups 
MTX (95% CI) Placebo (95% CI) P-Value MTX – Placebo (95% CI) 
-1.4 (-2.9 to 0.1) 0.3 (-1.8 to 2.4) 0.29 -1.7 (-4.9 to 1.5) 
MMT (12 month change); method: t-test, 2 sided; groups: All Groups 
MTX (95% CI) Placebo (95% CI) P-Value MTX – Placebo (95% CI) 
-5.5 (-7.4 to 3.8) -3.3 (-6.6 to 0.1) 0.28 -2.2 (-6.3 to 1.8) 
MGQOL (12 month change); method: Wilcoxon (Mann-Whitney); groups: All Groups 
MTX (95% CI) Placebo (95% CI) P-Value MTX – Placebo (95% CI) 
-4.6 (-9.1 to 0.1) -3.7 (-8.4 to 1.0) 0.82 -0.9 (-7.2 to 5.4) 
MG-ADL (12 month change); method: t-test, 2 sided; groups: All Groups 
MTX (95% CI) Placebo (95% CI) P-Value MTX – Placebo (95% CI) 
-1.2 (-2.3 to 0.5) 0.26 (-0.9 to 1.5) 0.21 -1.5 (-3.7 to 0.8) 
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MG Composite Change over 12 months; method: t-test, 2 sided; groups: All Groups 
MTX (95% CI) Placebo (95% CI) P-Value MTX – Placebo (95% CI) 
-4.6 (-6.4 to 2.7) -1.3 (-3.7 to 1.1) 0.09 -3.3 (-7.1 to 0.5) 
*General Note – if a study participant terminated their participation, their last results were pulled forward. 
 
The estimate of the treatment effect is not precise due to the fact that all of the p-values 
are >0.05, showing that they are not statistically significant due to the small sample size.  The 
small sample size also attributes to the CI ranges being too wide to be precise.  One participant 
from the MTX group withdrew from the study due to travel problems.  Seven participants from 
the Placebo group withdrew from the study due to the following reasons:  3 due to worsening of 
symptoms, 1 due to myalgia, 1 due to comorbid illness, 1 due to elevated LFTs, and 1 due to 
death (stroke). Safety was assessed by adverse event reporting.  No MTX subjects experienced 
any serious adverse events, therefore the study was deemed safe.  23 out of 25 (92%) participants 
from each group experienced some form of adverse event during the 12 month study, though 
66% of these events were determined to be unrelated to the study.  Most notably, the MTX group 
experience more GI issues, including upset stomach, diarrhea or constipation (MTX 60%; 
Placebo 44%).  The MTX group also experienced more sinus infections or URIs (MTX 52%; 
Placebo 28%).  Both group’s participants experienced similar adverse events of general fatigue 
(MTX 40%; Placebo 32%), general pain (MTX 52%; Placebo 56%; most common adverse 
event), and worsening of MG symptoms (MTX 40%; Placebo 32%).1,4,5,9  
If MTX was proven to be effective in treating MG symptoms and reducing the use of 
Prednisone, patients would have been able to benefit from MTX’s oral weekly dosing, including 
a generic formulation, a moderate side effect profile, inexpensive cost, easy availability, and 
potential use for longer periods of time.  Unfortunately, MTX did not perform as the study had 
hoped in reducing MG symptoms and improving the MG patient’s quality of life.1,4,5,9 
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DISCUSSION 
MTX was well tolerated in both RCTs, showing only its typical benign side effects such 
as GI upset. None of its more serious side effects surfaced during the studies, which include 
stomatitis, rash, abnormal blood counts and pulmonary toxicity. Folic acid concomitantly is 
required to help avoid these side effects.  MTX is also teratogenic therefore women of child-
bearing age need to weigh the risk versus benefit of the use of this agent and use several forms of 
birth control while using this agent.11   
The major limitation of both RCTs was the smaller than anticipated size of the study due 
to recruiting issues which, resulted in the data being not statistically significant2,9.  Also due to 
the limited funding of one study, several socioeconomically challenged participants were not 
about to be blinded due to AZA’s more expensive cost; this could have led to biases against 
MTX when reporting symptom improvement2.  The researchers of the most recent RCT also are 
considering that perhaps their study was not long enough with its 12 months duration, they 
referenced the prior RCT which compared AZA vs. MTX, which indicated that AZA required up 
to 15 months to reach its full therapeutic potential.  Another weakness the researchers considered 
was that their study contained an older mean age in their population (mid-60s), which means the 
study population included more late-onset MG subjects.  The significance in this being that 
patients with later onset of MG, tend to have a milder course of symptoms than younger patients 
with MG.  Milder symptoms could make detecting MTX’s benefits more difficult than in studies 
with younger MG subjects.  In the RCT comparing AZA vs. MTX, the mean age was 20 years 
younger (mid-40s) and the MTX effects seemed more significant.9,10   
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CONCLUSION 
 The results of the Case Series Study and earlier Single-blind RCT showed promise that 
MTX could be an effective treatment in partially or totally reducing the symptoms of MG 
patients.  However, the most recent Double-blind RCT suggests that MTX is no more effective 
in reducing symptoms in MG than a placebo, when both are paired with Prednisone. 
 Dr. Daniel Drachman, MD from the John Hopkins School of Medicine Neurology 
Department, responded to the disappointing negative results of this last MTX RCT.  He feels that 
a meaningful RCT for a new Gold Standard therapy for MG is nearly impossible at this point.  
His belief stems from the fact that MG has been found to be the most treatable autoimmune 
disease and therefore virtually all diagnosed MG patients start treatment immediately.  This 
makes recruitment for future studies extremely difficult, which both RCTs had experienced.  
Also the early and effective treatment of MG patients with Prednisone, makes gauging any new 
immunosuppressant’s effectiveness controversial and unreliable.8 
When looking ahead at future therapies for MG, various monoclonal antibodies such as 
Alemtuzumab, Belimumab, Eculizumab, Etanercept, and immunomodulatory drug Leflunomide 
may be the next generation of Gold Standard MG agents.  These chemical and biological agents 
target different components of the immune system and may have a role in improving the 
treatment of MG.11 Though MTX may not be the next Gold Standard agent for MG, researchers 
did learn some valuable lessons for future studies. The MG community needs to carefully 
consider which agents they study next.  This is due to the need for larger numbers of participants, 
a very limited commodity in this population, that will need to be followed for long periods of 
time, to ensure the study captures the full treatment effect of the agent.9 
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